Published in Int Immunopharmacol on October 01, 2003
Opioid-induced preconditioning is dependent on caveolin-3 expression. Anesth Analg (2010) 0.81
Functional evidence of des-Arg10-kallidin enzymatic inactivating pathway in isolated human umbilical vein. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.75
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension (2007) 1.93
The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci (2005) 1.87
Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors. Hypertension (2003) 1.56
Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. Transfusion (2007) 1.49
Contribution of endogenous endothelin in the enhanced coronary constriction in DOCA-salt hypertensive rats. J Hypertens (2003) 1.41
Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. J Hypertens (2003) 1.40
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet (2005) 1.29
Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am (2006) 1.12
Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther (2002) 1.12
Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke (2002) 1.11
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation (2002) 1.11
Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials. Biomaterials (2002) 0.98
Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. J Am Coll Cardiol (2002) 0.95
Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation (2002) 0.94
Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis. Arthritis Rheum (2005) 0.94
Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci (2003) 0.94
Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol (2003) 0.93
Kinin receptors: functional aspects. Int Immunopharmacol (2002) 0.92
Lack of direct interaction between enalaprilat and the kinin B1 receptors. Peptides (2007) 0.90
Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Curr Opin Pharmacol (2002) 0.89
Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res (2002) 0.89
Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. Life Sci (2007) 0.89
Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats. Am J Physiol Gastrointest Liver Physiol (2002) 0.88
Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol (2007) 0.88
Human recombinant membrane-bound aminopeptidase P: production of a soluble form and characterization using novel, internally quenched fluorescent substrates. Biochem J (2005) 0.87
A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells. Peptides (2010) 0.86
Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovasc Res (2005) 0.85
Signaling pathways involved in the cardioprotective effects of cannabinoids. J Pharmacol Sci (2006) 0.84
Role of nitric oxide and protein kinase C in the tachyphylaxis to vasopressin in rat aortic rings. Life Sci (2005) 0.83
Role of nuclear factor-kappaB and protein kinase C signaling in the expression of the kinin B1 receptor in human vascular smooth muscle cells. Mol Pharmacol (2006) 0.82
A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am J Pathol (2004) 0.82
Chronic antioxidant treatment improves sympathetic functions and beta-adrenergic pathway in the spontaneously hypertensive rats. J Hypertens (2003) 0.82
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat (2011) 0.81
Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure. Mol Cell Biochem (2003) 0.81
Inhibition of human and rabbit arterial smooth muscle cell migration mediated by the kinin B1 receptor: role of receptor density and released mediators. Can J Physiol Pharmacol (2006) 0.81
Studies on rabbit natural and recombinant tissue factors: intracellular retention and regulation of surface expression in cultured cells. Am J Physiol Heart Circ Physiol (2005) 0.81
Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression. J Pharmacol Exp Ther (2009) 0.81
Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor? Am J Physiol Heart Circ Physiol (2003) 0.81
Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors. Br J Pharmacol (2009) 0.81
Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol (2002) 0.80
Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation. Transfusion (2002) 0.80
Effect of interferon-γ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells. Eur J Pharmacol (2010) 0.80
Rescue of amitriptyline-intoxicated hearts with nanosized vesicles. Cardiovasc Res (2007) 0.80
Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion (2004) 0.80
The syndrome of amniotic fluid embolism: a potential contribution of bradykinin. Am J Obstet Gynecol (2005) 0.79
Kinin B1 receptors contributes to acute pain following minor surgery in humans. Mol Pain (2010) 0.79
Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression. Can J Physiol Pharmacol (2002) 0.79
The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes. Biomaterials (2008) 0.79
A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging. Peptides (2008) 0.79
Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation. J Pharmacol Exp Ther (2005) 0.78
Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue. Pharmacol Res (2011) 0.78
Characterization of currently marketed heparin products: adverse event relevant bioassays. J Pharm Biomed Anal (2012) 0.77
Chronic intestinal inflammation and angiogenesis in genetically susceptible rats is modulated by kininogen deficiency. Int Immunopharmacol (2002) 0.77
Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: effects of LPS, anti-inflammatory and anti-hypertensive drugs. Regul Pept (2007) 0.77
Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol (2002) 0.77
Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta. J Pharmacol Exp Ther (2005) 0.76
Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. J Cardiovasc Pharmacol (2002) 0.75
Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism. J Pharmacol Exp Ther (2005) 0.75
The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides. Can J Physiol Pharmacol (2005) 0.75
Vasopeptidase inhibition peri- and post-MI in Zucker insulin resistant rats: effect on MI size, arrhythmias, remodeling, function and fetal gene expression. Cardiovasc Drugs Ther (2005) 0.75
Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity. Liver Transpl (2008) 0.75
Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle. Eur J Pharmacol (2009) 0.75
The bradykinin B2 receptor antagonist icatibant (Hoe 140) blocks aminopeptidase N at micromolar concentrations: off-target alterations of signaling mediated by the bradykinin B1 and angiotensin receptors. Eur J Pharmacol (2006) 0.75
Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction. Can J Physiol Pharmacol (2003) 0.75
Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats. Can J Cardiol (2005) 0.75